Valuation: AP Biosciences, Inc.

Market Cap	10.86B 337M 295M 272M 252M 478M 32.21B 486M 3.26B 1.28B 15.82B 1.27B 1.24B 54.79B	P/E 2024	-8.86x	P/E 2025	-34.4x
Enterprise Value	9.75B 303M 265M 244M 226M 429M 28.92B 436M 2.93B 1.15B 14.2B 1.14B 1.11B 49.19B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	36.96%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : AP Biosciences, Inc.

05-15	AP Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Delos Capital and AP Biosciences Inc. Launch Collaboration to Create New Biotech Companies Focused on Next-Generation Antibodies	CI
03-31	AP Biosciences, Inc. has filed an IPO in the amount of TWD 1.2562 billion.	CI
03-23	AP Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-22	AP Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/08/25	AP Biosciences, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
14/05/25	AP Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
29/04/25	AP Biosciences Presents Preclinical Data on P95her/Cd137 T-Cell Engager At American Association of Cancer Research Annual Meeting	CI
22/04/25	AP Biosciences Doses First Patient In Phase 1/2 Clinical Trials Of AP402 For HER2+ Cancer Patients	RE
22/04/25	AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients	CI
21/04/25	AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual Meeting	CI
13/08/24	AP Biosciences Inc Reports Earnings Results for the Half Year Ended June 30, 2024	CI
19/03/24	AP Biosciences Inc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

More news

Press Releases: AP Biosciences, Inc.

24/07/25

Designing antibodies to think before they bind

More press releases

Managers and Directors: AP Biosciences, Inc.

Manager	Title	Age	Since
Jeng-Horng Her CEO	Chief Executive Officer	-	27/05/2013
Shu Cheng Lin DFI	Director of Finance/CFO	-	18/10/2022
Wan Ju Tseng ADM	Chief Administrative Officer	-	18/10/2022

Director	Title	Age	Since
Chih Chuan Chen CHM	Chairman	-	23/05/2023
Jeng-Horng Her BRD	Director/Board Member	-	09/11/2022
Shih Ming Lin BRD	Director/Board Member	-	23/05/2023

More insiders

AP Biosciences Inc is a Taiwan-based company mainly engaged in the research and development of protein drugs and antibody drugs. The Company develops early candidate drugs and preclinical trials, and develops different monoclonal or bispecific antibody drugs for potential targets, mechanisms of action, and disease characteristics through drug design and existing technology platforms. The Company's technology platform and bispecific protein drug research and development projects include IBI302-anti-vascular endothelial growth factor (VEGF) and anti-complement bifunctional recombinant protein, OmniMab fully human antibody library, AP505-PD-L1 x VEGF bispecific antibody, target-directed T cell activation 3T platform (T-cube), AP203-PD-L1 x CD137 fully human bispecific antibody, and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
09/07/26	NT$112.00	-5.08%	686,770
08/07/26	NT$118.00	+3.06%	1,507,220
07/07/26	NT$114.50	+9.57%	1,092,860
06/07/26	NT$104.50	-0.48%	602,760
03/07/26	NT$105.00	+7.69%	673,043

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Taipei Exchange Other stock markets 09/07/2026			5-day change	1st Jan Change
112.00 ^TWD	-5.08%		+14.87%	-37.78%

1 day	-5.08%
1 week	+14.87%
Current month	+10.89%
1 month	+9.80%
3 months	-42.12%
6 months	-33.33%
Current year	-37.78%

1 week	103	120.5
1 month	92.5	120.5
Current year	92.5	236
1 year	52.5	236
3 years	36.3	236
5 years	36.3	236
10 years	36.3	236

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AP BIOSCIENCES, INC.	-5.08%	+14.87%	+105.13%	-	337M
ARGENX SE	-0.63%	-4.69%	+63.12%	+125.20%	56.98B
WUXI APPTEC CO., LTD.	+4.91%	-0.19%	+73.70%	+92.14%	53.58B
INSMED INCORPORATED	+1.48%	+5.97%	+22.59%	+495.47%	25.63B
BIONTECH SE	-0.59%	-4.68%	-16.82%	-12.99%	23.51B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+47.70%	-0.11%	19.43B
GENMAB A/S	-1.52%	+1.74%	+36.32%	-25.60%	18.12B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+203.03%	+348.11%	16.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+53.81%	-	14.13B
EXELIXIS, INC.	+1.76%	+2.24%	+29.57%	+195.70%	14.35B
Average	+0.47%	+1.44%	+61.82%	+152.24%	24.25B
Weighted average by Cap.	+1.26%	-0.30%	+57.21%	+142.66%

	2024	2025
Net sales	-	-
Net income	-423M -13.13M -11.49M -10.59M -9.8M -18.6M -1.25B -18.92M -127M -49.73M -616M -49.3M -48.23M -2.13B	-445M -13.82M -12.09M -11.15M -10.31M -19.57M -1.32B -19.9M -133M -52.32M -648M -51.87M -50.75M -2.24B
Net Debt	-1.47B -45.69M -39.97M -36.86M -34.1M -64.73M -4.36B -65.81M -441M -173M -2.14B -172M -168M -7.42B	-1.11B -34.52M -30.2M -27.85M -25.77M -48.91M -3.3B -49.73M -334M -131M -1.62B -130M -127M -5.61B

AP Biosciences, Inc. Stock

Stocks

6945

TW0006945009

Biotechnology & Medical Research

Valuation: AP Biosciences, Inc.

Chart: AP Biosciences, Inc.

Latest news : AP Biosciences, Inc.

Press Releases: AP Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AP Biosciences, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates